What Changed
Price Move History
- Daily moves over 5%
- 45 252 sessions, November 13, 2025 to November 13, 2026
- Largest daily move
- +19.9% close of August 18, 2026
- 1-year change
- +73.4% closing prices, November 13, 2025 to November 13, 2026
- 1-month change
- +26.7% closing prices, October 13, 2026 to November 13, 2026
Company Description
Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) is a biomedical innovation company that focuses on accelerating high-impact technologies to patients through strategic collaborations and risk-reward sharing partnerships with global medical device companies. According to the company’s disclosures, its partnership-enabled business model centers on forging long-term, strategically aligned relationships to drive development and commercialization of its product candidates.
The company’s lead programs are two flagship product candidates that target major cardiovascular conditions. Atrioventricular Interval Modulation (AVIM) Therapy, also referred to as BackBeat Cardiac Neuromodulation Therapy (CNT), is described as a bioelectronic treatment for hypertension, which the company characterizes as the leading risk factor for death worldwide. AVIM Therapy is designed to be delivered as a firmware upgrade to a standard dual-chamber pacemaker and is intended to achieve immediate, substantial and sustained reductions in blood pressure in patients with hypertensive heart disease who are indicated for a pacemaker. The therapy has been evaluated in pilot studies and is being advanced in the BACKBEAT global pivotal study for patients with systolic blood pressure above target despite anti-hypertensive medication and who are indicated for or have recently received a dual-chamber cardiac pacemaker.
Orchestra BioMed reports that AVIM Therapy has received FDA Breakthrough Device Designation for the treatment of uncontrolled hypertension in patients with increased cardiovascular risk, including an estimated 7.7 million patients in the U.S. with uncontrolled hypertension despite medical therapy. The company also notes a strategic collaboration with Medtronic, described as one of the largest medical device companies in the world, for development and commercialization of AVIM Therapy in pacemaker-indicated patients. An amendment to this collaboration provides a framework for potential future integration of AVIM Therapy into dual-chamber leadless pacemakers.
The company’s second flagship program is the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB), a drug delivery angioplasty balloon system designed to deliver a proprietary extended-release formulation of sirolimus, known as SirolimusEFR. Virtue SAB uses a non-coated microporous AngioInfusion Balloon to protect the drug in transit and deliver a large liquid dose directly to the vessel wall. Company materials describe Virtue SAB as a highly differentiated, first-of-its-kind system intended for the treatment of atherosclerotic artery disease, which it characterizes as the leading cause of mortality worldwide.
Virtue SAB has been studied in preclinical and clinical settings. Published preclinical work cited by the company indicates that SirolimusEFR delivered by Virtue SAB can achieve sustained tissue levels above a known therapeutic concentration for inhibiting restenosis through a critical healing period of approximately 30 days. In the SABRE clinical study in Europe, Virtue SAB demonstrated positive three-year data in coronary in-stent restenosis (ISR) in a multi-center, prospective, independent core lab-adjudicated study. Orchestra BioMed states that Virtue SAB has FDA Breakthrough Device Designation for the treatment of coronary ISR, coronary small vessel disease and below-the-knee peripheral artery disease.
Both AVIM Therapy and Virtue SAB are described by the company as being in pivotal clinical trials for their lead indications, which it characterizes as multi-billion-dollar annual global market opportunities. The Virtue Trial, a U.S. investigational device exemption (IDE) pivotal trial, is a randomized head-to-head coronary study comparing Virtue SAB to the AGENT paclitaxel-coated balloon for treatment of coronary ISR. The trial is designed to support regulatory approval in the United States and is expected to enroll hundreds of patients across multiple centers.
Orchestra BioMed emphasizes a partnership-driven approach to advancing these programs. The company has a strategic collaboration with Medtronic for AVIM Therapy and has entered into a right of first refusal agreement with Terumo Corporation and Terumo Medical Corporation related to potential future transactions involving Virtue SAB for coronary artery disease. Under this arrangement, Terumo has a right of first refusal on certain Virtue SAB coronary transactions, while Orchestra BioMed retains development and distribution rights across all indications. The company has also entered into a revenue participation right purchase and sale agreement with Ligand Pharmaceuticals Incorporated, under which Ligand receives tiered revenue participation tied to future revenues from AVIM Therapy and Virtue SAB in specified fields.
In addition to its core programs, Orchestra BioMed has engaged in strategic investments and capital transactions to support its clinical and development activities. These include public equity offerings, private placements of common stock, issuance of pre-funded warrants, and preferred stock financings. The company has also entered into a secured subordinated convertible loan agreement with Medtronic that can convert into a share of revenue associated with AVIM Therapy if specified regulatory milestones are achieved.
Orchestra BioMed describes itself as an emerging growth company and a biomedical innovation platform that seeks to align with market-leading medical device partners to advance device-based therapies for cardiovascular disease. Its disclosures highlight hypertension and atherosclerotic artery disease as central disease areas, with AVIM Therapy and Virtue SAB positioned as investigational approaches that aim to address unmet needs in hypertensive heart disease, coronary ISR, coronary small vessel disease and below-the-knee peripheral artery disease.
Business model and partnerships
The company’s stated business model is based on risk-reward sharing partnerships and strategic collaborations. It reports that this model is intended to combine its internal development capabilities with the scale and commercial infrastructure of larger medical device companies. Examples include the collaboration with Medtronic for AVIM Therapy and agreements with Terumo related to Virtue SAB. The company has also structured revenue participation and financing arrangements, such as its agreement with Ligand, that are tied to future product revenues.
Clinical development focus
Orchestra BioMed’s disclosures emphasize pivotal-stage clinical development. The BACKBEAT global pivotal study is designed to evaluate AVIM Therapy in patients with uncontrolled hypertension who are indicated for a dual-chamber pacemaker. The Virtue Trial is described as a U.S. IDE pivotal trial comparing Virtue SAB to a commercially available paclitaxel-coated balloon in coronary ISR. These trials are intended to generate data to support regulatory submissions and potential commercialization pathways in collaboration with partners.
Capital markets and regulatory status
Orchestra BioMed’s securities filings indicate that the company has conducted underwritten public offerings of common stock and pre-funded warrants, as well as concurrent private placements with institutional partners. It has also entered into agreements that provide tiered revenue interests and convertible debt tied to the performance and commercialization of its flagship programs. The company identifies itself as an emerging growth company under applicable U.S. securities regulations and files current reports on Form 8-K to disclose material agreements, financings and investor presentations.
Stock Performance
Orchestra BioMed Holdings (OBIO) closed at $7.25 on November 13, 2026. Over the past 12 months, the price has gained 73.4%.
OBIO Metrics & Rankings
Price returns through November 13, 2026. Month and year figures include the first trading day. Ranking links may use different dates.
Latest News
Orchestra BioMed Holdings has 10 recent news articles, with the latest published 6 days ago. Of the recent coverage, 6 articles coincided with positive price movement and 4 with negative movement. Key topics include earnings, offering, acquisition. View all OBIO news →
SEC Filings
Orchestra BioMed Holdings has filed 10 recent SEC filings, including 5 Form 4, 2 Form 424B5, 1 Form SCHEDULE 13D/A, 1 Form 10-Q. The most recent filing was submitted on . SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all OBIO SEC filings →
Insider Radar
Insider buying activity at Orchestra BioMed Holdings over the past 90 days may reflect management confidence in the company's direction. Institutional investors and analysts often monitor insider purchases as a potential bullish indicator for the stock.
Financial Highlights
Orchestra BioMed Holdings generated $33.5M in revenue in FY2025, retaining a 99.4% gross margin, operating income reached -$51.8M, and net income was -$52.7M. Diluted earnings per share stood at -$1.11. The company generated -$49.0M in operating cash flow. The current ratio was 6.45, measuring current assets divided by current liabilities.
Upcoming Events
Underwriter option expiration
Underwriter option expiry
HRS 2027 presentation
Virtue enrollment completion
Late-breaking submission
Primary endpoint presentation
Late-breaking data presentation
Enrollment completion planned
Virtue Trial enrollment milestone
Options final vesting
Orchestra BioMed Holdings has 11 upcoming scheduled events. The next event, "Underwriter option expiration", is scheduled for December 5, 2026 (in 19 days). 2 of them are financing or capital events, such as a dividend or a debt maturity. Investors can track these dates to stay informed about potential catalysts that may affect the OBIO stock price.
Short Interest History
Short interest in Orchestra BioMed Holdings (OBIO) currently stands at 2.7 million shares, up 7.0% from the previous reporting period, representing 4.6% of the float. Since November 2025, short interest has increased by 252.9%.
Days to Cover History
Days to cover for Orchestra BioMed Holdings (OBIO) currently stands at 7.0 days, down 27.9% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 253%. Across the settlements charted above, it has ranged from 2.0 to 13.4 days.
OBIO Company Profile & Sector Positioning
Orchestra BioMed Holdings (OBIO) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.
Investors comparing OBIO often look at related companies in the same sector, including Eupraxia Pharmaceuticals Inc. (EPRX), Aclaris Therapeutics, Inc. (ACRS), Capricor Therapeutics Inc (CAPR), Valneva SE (VALN), and Olema Oncology, Inc. (OLMA). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate OBIO's relative position within its industry.